infectious diseases
Smallpox
Treatment of Smallpox
Supportive care Isolation Possiblytecovirimat, considercidofovirorbrincidofovir(CMX 001) was approved by the US Food and Drug Administration (FDA) in 2018 ( Treatment references ) and, in June 2021, the FDA approved Isolation of people with smallpox is essential. In limited outbreaks, patients may be isolated in a hospital under airborne transmission precautions in an airborne-infection isolation room. In mass outbreaks, home isolation may be required. Contacts should be placed under surveillance, typically with daily temperature measurement; if they develop a temperature of>38°C or other sign of illness, they should be isolated at home. 1.Grosenbach DW, Honeychurch K, Rose EA, et al: Oraltecovirimatfor the treatment of smallpox.N Engl J Med5;379(1):44-53, 2018. doi: 10.1056/NEJMoa1705688 2.Chittick G, Morrison M, Brundage T, et al: Short-term clinical safety profile ofbrincidofovir: A favorable benefit-risk proposition in the treatment of smallpox.Antiviral Res143:269–277, 2017. doi: 10.1016/j.antiviral.2017.01.009 3.Chan-Tack K, Harrington P, Bensman T, et al: Benefit-risk assessment forbrincidofovirfor the treatment of smallpox: U.S. Food and Drug Administration's Evaluation.Antiviral Res195:105182, 2021. doi: 10.1016/j.antiviral.2021.105182. Epub 2021 Sep 25. PMID: 34582915. 